You are watching a 25-second preview
Log in to keep watching
Your 25-second video preview has ended.
to continue watching, please Log In or Register:
Jeffrey Gross, MD, discusses the DRCR.net Protocol S study. Researchers evaluated the safety and efficacy of ranibizumab versus PRP in the treatment of proliferative diabetic retinopathy. PRP has historically been very effective in PDR treatment, but may result in adverse side effects. Dr. Gross details the study’s clinical data, explains the differences in results between the two treatments, and says why ranibizumab may be an alternative treatment for PDR.
9,191 video views since 11/17/2015.
85,643 total series views.
These programs are not affiliated with the official program of AAO 2015.